NexgenRx Inc.
NEGXF
$0.1964
$0.00492.56%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.13% | 0.37% | 8.53% | 21.67% | 14.66% |
| Total Other Revenue | 94.12% | 35.52% | -21.38% | -2.69% | 13.67% |
| Total Revenue | 7.53% | 1.59% | 7.12% | 20.64% | 14.62% |
| Cost of Revenue | -4.88% | 8.14% | -33.21% | 32.80% | 6.69% |
| Gross Profit | 10.72% | 0.04% | 19.24% | 17.27% | 16.86% |
| SG&A Expenses | 3.36% | -0.46% | -6.12% | 8.10% | 17.01% |
| Depreciation & Amortization | -0.89% | -7.48% | -3.67% | -5.41% | -5.99% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.29% | 0.80% | -11.76% | 12.03% | 12.47% |
| Operating Income | 296.44% | 7.70% | 279.44% | 246.08% | 880.95% |
| Income Before Tax | 3,521.21% | 8.16% | 250.00% | 181.75% | 128.21% |
| Income Tax Expenses | 1.20% | 6.47% | 396.96% | -5.66% | 1.76% |
| Earnings from Continuing Operations | 996.57% | 7.43% | 93.09% | 212.21% | 464.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 996.57% | 7.43% | 93.09% | 212.21% | 464.06% |
| EBIT | 296.44% | 7.70% | 279.44% | 246.08% | 880.95% |
| EBITDA | 60.91% | -2.03% | 888.50% | 124.57% | 15.77% |
| EPS Basic | 1,100.00% | 6.67% | 62.30% | 207.14% | 400.00% |
| Normalized Basic EPS | 1,800.00% | 6.90% | 252.63% | 180.00% | 150.00% |
| EPS Diluted | 1,100.00% | -6.67% | 64.18% | 200.00% | 400.00% |
| Normalized Diluted EPS | 1,600.00% | 3.57% | 252.63% | 188.89% | 150.00% |
| Average Basic Shares Outstanding | 0.28% | 0.28% | -0.09% | 0.78% | 0.83% |
| Average Diluted Shares Outstanding | 0.00% | 5.49% | -0.09% | 1.13% | 1.69% |
| Dividend Per Share | -2.70% | -- | -2.70% | -- | 0.00% |
| Payout Ratio | -0.91% | -0.13% | -2.43% | 1.88% | 1.25% |